Climbing Numbers of Chronic Conditions Drive API Market
The growing pool of geriatrics is driving the demand for various types of drugs, which in turn is leading to a soaring demand of active pharmaceutical ingredient (API) market. Active pharmaceutical ingredients are primarily used for making drugs that are used for treating a range of chronic conditions such as cancer, metabolic disorders, cardiovascular diseases, neurology disorders as well as for other therapeutic uses. Given this strong background, Transparency Market research states the opportunity in this market will be worth US$219.60 bn by 2023 from US$134.7 bn in 2015. Between the forecast period of 2015 and 2023, the overall market is expected to expand at a CAGR of 6.3%.
The improving access to healthcare with the rapid penetration of technology and other developments in the healthcare sector has also increased the consumption of drugs, thereby directly creating a positive impact on this market. Furthermore, growing healthcare budgets of developed and developing countries are also making a significant contribution towards propelling the sale of active pharmaceutical ingredient market. Furthermore, the compliance by Indian active pharmaceutical ingredients manufacturers with U.S. FDA norms is also anticipated to result in increasing applications of this substance.
Complicated Cardiovascular Diseases to Keep Fueling Demand for APIs
As of 2015, the high incidence of cardiovascular diseases, neurological disorders, and other metabolic disorders led these therapeutic segments to account for a collective share of 50% in the global market. In the forecast period, the prevalence of complicated cardiovascular conditions is going to propel this therapeutic area at a 6.63% CAGR. Furthermore, as the majority of the blockbuster drugs lost patents between 2011 and 2015, it has opened a huge ground for other companies to introduce their drugs, thereby increasing the competition and probably reducing costs.
Asia Pacific to Emerge as Key Manufacturer of APIs
As of 2014, North America held a dominant share in the overall market, accounting for about 35.1% share in the market. The presence of big pharmaceutical companies in North America that require large amounts of active pharmaceutical ingredients is the major factor driving the API market in North America. Analysts predict that introduction of biosimilars as the regulatory process get relaxed will further accelerate the consumption of active pharmaceutical ingredients in North America. The active pharmaceutical ingredients manufacturing will experience an upsurge in the emerging economies of Japan, China, South Korea, and India due to the presence of manufacturing facilities and cheap cost of labor.
Some of the leading companies operating in the global active pharmaceutical ingredient market are Zhejiang Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., Zhejiang NHU Co., Ltd , North China Pharmaceutical Group Corp. (NCPC), Dr.Reddy's Laboratories Limited, Northeast Pharmaceutical Group Co., Ltd., Aurobindo Pharma Limited, Sandoz (Novartis AG), Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. amongst others. Currently, these players are focusing on partnering with other companies to acquire a new line of products to add value to their portfolio. Furthermore, companies are also anticipated to focus on expanding their capacities to cater to the vast unmet medical needs of the world.
Chapter 1 Preface
Chapter 2 Executive Summary
2.2 Global Active Pharmaceutical Ingredients Market: Market Snapshot
2.3 Comparative Analysis: Global Active Pharmaceutical Ingredients Market, by Geography (2015 & 2023)
2.4 Waterfall Diagram: Global API Market Revenue, by Therapeutic Area, 2015 (US$ Mn)
Chapter 3 Market Overview
3.2 Market Dynamics
22.214.171.124 Increase in healthcare expenditure to drive market growth
126.96.36.199 Rapidly aging of global population expected to aid growth of the API market
188.8.131.52 Increase in Abbreviated New Drug Applications (ANDA) in the recent past to boost the demand for APIs
184.108.40.206 Adverse regulatory policies to be an important restraining factor
220.127.116.11 Patent Expiry of Major Biological Drugs in the U.S. and EU
18.104.22.168 Growth of the healthcare market in Asia-Pacific and rest of the world (RoW) segments
3.3 Event Impact Analysis
3.4 Value Chain Analysis
3.5 Porter’s Five Forces Analysis
3.6 Market Attractiveness Analysis: Global Active Pharmaceutical Ingredients Market, by Geography, 2015
3.7 Competitive Landscape: Global Active Pharmaceutical Ingredients Market, by Key Players, 2015 (USD Million)
Chapter 4 By Manufacturing Process
4.2 Captive Manufacturing Market Revenue, 2013-2023 (US$ Mn)
4.3 Contract Manufacturing Market Revenue, 2013-2023 (US$ Mn)
Chapter 5 By API Type
5.2 Synthetic Chemical Market Revenue, 2013-2023 (US$ Mn)
5.3 API Biological API Market Revenue, 2013-2023 (US$ Mn)
Chapter 6 By Drug Type
6.2 API Market Revenue for Branded Prescription Drugs, 2013-2023 (US$ Mn)
6.3 API Market Revenue for Generic Prescription Drugs, 2013-2023 (US$ Mn)
6.4 API Market Revenue for OTC Prescription Drugs, 2013-2023 (US$ Mn)
Chapter 7 By Therapeutic Area
7.2 API Market Revenue for Cardiovascular Disorders Drug, 2013-2023 (US$ Mn)
7.3 API Market for Drugs for Metabolic Disorders, 2013-2023 (US$ Mn)
7.4 API Market for Drugs for Neurological Disorders, 2013-2023 (US$ Mn)
7.5 API Market for Drugs for Oncology, 2013-2023 (US$ Mn)
7.6 API Market for Drugs for Musculoskeletal Disorders, 2013-2023 (US$ Mn)
7.7 API Market for NSAIDs, 2013-2023 (US$ Mn)
7.8 API Market for Drugs for Other Therapeutics Uses, 2013-2023 (US$ Mn)
Chapter 8 By Region
8.2 North America API Market Revenue, by Country, 2013-2023 (US$ Mn)
8.2.1 U.S. API Market Revenue,, 2013–2023, (US$ Mn)
8.2.2 Canada API Market Revenue, 2013–2023, (US$ Mn)
8.3 Asia-Pacific Market Revenue, by Country, 2013-2023 (US$ Mn)
8.3.1 China API Market Revenue,, 2013–2023, (US$ Mn)
8.3.2 Japan API Market Revenue,, 2013–2023, (US$ Mn)
8.3.3 India API Market Revenue,, 2013–2023, (US$ Mn)
8.3.4 Rest of Asia-Pacific API Market Revenue,, 2013–2023, (US$ Mn)
8.4.1 Germany API Market Revenue,, 2013–2023, (US$ Mn)
8.4.2 U.K. API Market Revenue,, 2013–2023, (US$ Mn)
8.4.3 Rest of Europe API Market Revenue,, 2013–2023, (US$ Mn)
8.5 Rest of the World
Chapter 9 Recommendations
9.1 Enhance manufacturing capacity through acquisitions in targeted geographies
9.2 Achieve cost leadership in specific API molecules
Chapter 10 Company Profiles
10.1 Allergan plc
10.2 BASF SE
10.3 Boehringer Ingelheim GmbH
10.4 Cambrex Corporation
10.5 Dr. Reddy's Laboratories
10.6 Lonza Group
10.7 Mylan N.V.
10.8 Pfizer, Inc.
10.9 Sandoz (Novartis AG)
10.10 Teva Pharmaceutical Industries Ltd.
10.11 WuXi AppTec
Active pharmaceutical ingredients (APIs) are bulk drug products that are used as raw materials for formulations. APIs of good quality are essential for the manufacture of effective and safe medicines. However, not all pharmaceutical companies possess in-house API manufacturing capabilities. Furthermore, a single company cannot produce all the APIs required for their formulation offerings.
The global active pharmaceutical ingredients market has been broadly segmented on the basis of manufacturing process, type of active pharmaceutical ingredient, types of drugs, therapeutic areas and geography. This report analyzes the current scenario as well as future market potential for active pharmaceutical ingredients market globally. This report comprises an elaborate executive summary, demonstrating a snapshot on market dynamics of various segments and sub-segments in a precise manner. Moreover, executive summary also comprises a waterfall chart, which reflects the market size of various segments in descending order.
The report provides detailed qualitative analysis of the market dynamics that affect the growth of the global active pharmaceutical ingredients market. Factors responsible for driving and restraining the growth of the global active pharmaceutical ingredients market and future opportunities has been provided in the market overview section. This section of the report also provides comprehensive market comparative analysis and market attractiveness analysis for the global active pharmaceutical ingredients market by geography for the base year, Porter’s Five Forces analysis, and market share analysis by key players (%) for the base year, operating in the active pharmaceutical ingredients market. The report also encompasses detailed event impact analysis and value chain analysis for the global active pharmaceutical ingredients market.
The global active pharmaceutical ingredient market is categorized in to captive manufacturing and contract manufacturing. Types of active pharmaceutical ingredients described in the global active pharmaceutical ingredient market include synthetic chemical API and biological API. Branded prescription drugs, generic prescription drugs, and over-the-counter drugs are various types of drugs covered in the global active pharmaceutical ingredients market. The global active pharmaceutical ingredients market encompasses various therapeutic areas such as cardiovascular disorders, oncology, metabolic disorders, neurological disorders, musculoskeletal disorders, NSAIDs and other therapeutic uses (such as infectious diseases). The market for these types has been extensively analyzed based on consistency, effectiveness, and sales revenue of the various products developed by the manufacturers.
Geographies discussed and analyzed in the global active pharmaceutical ingredients market include North America, Europe, Asia Pacific, and Rest of the World. In addition the report also comprises the precise and detailed country wise analysis for the global active pharmaceutical ingredients market such as North America (U.S. and Canada), Asia Pacific (China, Japan, India and Rest of Asia Pacific), and Europe (Germany, U.K. and Rest of Europe). The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2013 to 2023. The report on the active pharmaceutical ingredients market also provides compound annual growth rate (CAGR %) for each of the market segments mentioned above for the forecast period from 2015 to 2023, considering 2014 as the base year.
A list of recommendations have been provided for new entrants to help establish a strong presence and for existing market players to take strategic decisions and to increase their market shares in the global active pharmaceutical ingredient market. The report concludes with the profiles of major players in the active pharmaceutical ingredients market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include Allergan plc, BASF SE, Boehringer Ingelheim Group, Cambrex Corporation, Dr. Reddy’s Laboratories Ltd., Lonza Group, Mylan, Inc., Sandoz (Novartis AG), Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and WuXi Apptec.
The global active pharmaceutical ingredients market is segmented as follows:
Global Active Pharmaceutical Ingredients Market, by Manufacturing Process, 2013-2023 (US$ Mn)
- Captive Manufacturing
- Contract Manufacturing
Global Active Pharmaceutical Ingredients Market, by API Type, 2013 – 2023 (US$ Mn)
- Synthetic Chemical API
- Biological API
Global Active Pharmaceutical Ingredients Market, by Drug Type, 2013 – 2023 (US$ Mn)
- Branded Prescription Drugs
- Generic Prescription Drugs
- OTC Prescription Drugs
Global Active Pharmaceutical Ingredients Market, by Therapeutic Area, 2013 – 2023 (US$ Mn)
- Cardiovascular Disorders
- Metabolic Disorders
- Neurological Disorders
- Musculoskeletal Disorders
- Other Therapeutics Uses
Global Active Pharmaceutical Ingredients Market, by Geography, 2013 – 2023 (US$ Mn)
- North America
- Rest of Europe
- Rest of Asia Pacific
- Rest of the World (RoW)